Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire.
Ahmad A TarhiniYan LinHuang LinZahra RahmanPriyanka VallabhaneniPrateek MendirattaJames F PingpankMatthew P HoltzmanErik C YuskoJulie A RytlewskiUma N M RaoRobert L FerrisJohn M KirkwoodPublished in: Journal for immunotherapy of cancer (2018)
ClinicalTrials.gov, NCT01608594 . Registered 31 May 2012.